Literature DB >> 10542098

Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.

J Mongkolsapaya1, J M Grimes, N Chen, X N Xu, D I Stuart, E Y Jones, G R Screaton.   

Abstract

TRAIL, an apoptosis inducing ligand, has at least four cell surface receptors including the death receptor DR5. Here we report the crystal structure at 2.2 A resolution of a complex between TRAIL and the extracellular region of DR5. TRAIL forms a central homotrimer around which three DR5 molecules bind. Radical differences in the surface charge of the ligand, together with variation in the alignment of the two receptor domains confer specificity between members of these ligand and receptor families. The existence of a switch mechanism allowing variation in receptor domain alignment may mean that it is possible to engineer receptors with multiple specificities by exploiting contact positions unique to individual receptor-ligand pairs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542098     DOI: 10.1038/14935

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  75 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors.

Authors:  Christopher C Valley; Andrew K Lewis; Jonathan N Sachs
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-01-12       Impact factor: 3.747

3.  RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.

Authors:  Tadashi Mori; Akihiro Oguro; Takashi Ohtsu; Yoshikazu Nakamura
Journal:  Nucleic Acids Res       Date:  2004-11-23       Impact factor: 16.971

Review 4.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 6.  Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.

Authors:  Francis Ka-Ming Chan
Journal:  Cytokine       Date:  2007-04-20       Impact factor: 3.861

7.  Crystallization and preliminary X-ray analysis of mouse RANK and its complex with RANKL.

Authors:  Thomas S Walter; Changzhen Liu; Peng Huang; Shiqian Zhang; Lucy R Wedderburn; Bin Gao; Raymond J Owens; David I Stuart; Peifu Tang; Jingshan Ren
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-22

8.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

9.  Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.

Authors:  Heather A Huet; Joseph D Growney; Jennifer A Johnson; Jing Li; Sanela Bilic; Lance Ostrom; Mohammad Zafari; Colleen Kowal; Guizhi Yang; Axelle Royo; Michael Jensen; Bruno Dombrecht; Kris R A Meerschaert; Joost A Kolkman; Karen D Cromie; Rebecca Mosher; Hui Gao; Alwin Schuller; Randi Isaacs; William R Sellers; Seth A Ettenberg
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 10.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.